SCHEMBL1032222

SCHEMBL1032222

COS(=O)(=O)c1ccc(-c2cocn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.39
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
HDAC4 P56524 1/20 0.37
CCR9 P51686 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
NAAA Q02083 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
IMPDH2 P12268 1/20 0.32
MMP13 P45452 1/20 0.32
MMP14 P50281 1/20 0.32
NPC1 O15118 1/20 0.32
NR2F2 P24468 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12878846 0.81 PTGS2 (0.45) EDNRBEDNRAHDAC4
SCHEMBL1033426 0.80 CCR9 (0.41) SCN9AEDNRBEDNRAHDAC4CCR9
SCHEMBL197570 0.74 CA12 (0.46) CA12CA1CA2CA9NPC1
SCHEMBL777482 0.72 PKM (0.46) CA12CA1CA2CA9MMP13
SCHEMBL31585545 0.71 NAAA (0.39) SCN9AEDNRBEDNRACA12CA1
SCHEMBL9288053 0.71 ENPP3 (0.47) SCN9AEDNRBEDNRAHDAC4NPC1
SCHEMBL20839501 0.71 ALDH1A1 (0.49) HDAC4CA12CA1CA2CA9
SCHEMBL30608939 0.71 CYP2D6 (0.49) SCN9AEDNRAHDAC4NPC1
SCHEMBL1951726 0.71 HDAC4 (0.46) SCN9AEDNRBEDNRAHDAC4CCR9
SCHEMBL7590340 0.71 CCR9 (0.36) SCN9AEDNRBEDNRAHDAC4CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383641-B2 Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO. KG (DE) 2013-02-26 US disclosed
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed
US-20090143383-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-06-04 US disclosed
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143383-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR SLC6A3, DRD3, MC3R SCN9A 2249/4885EDNRB 172/4885EDNRA 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.